Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites.

Pappalardi MB, McNulty DE, Martin JD, Fisher KE, Jiang Y, Burns MC, Zhao H, Ho T, Sweitzer S, Schwartz B, Annan RS, Copeland RA, Tummino PJ, Luo L.

Biochem J. 2011 Jun 1;436(2):363-9. doi: 10.1042/BJ20101201.

PMID:
21410436
2.

Hypoxia-inducible factor prolyl-hydroxylase: purification and assays of PHD2.

Hewitson KS, Schofield CJ, Ratcliffe PJ.

Methods Enzymol. 2007;435:25-42.

PMID:
17998047
3.

Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing.

Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Bürgel T, Jelkmann W, Acker H, Fandrey J.

J Cell Sci. 2003 Apr 1;116(Pt 7):1319-26.

4.
5.

Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases.

Koivunen P, Hirsilä M, Günzler V, Kivirikko KI, Myllyharju J.

J Biol Chem. 2004 Mar 12;279(11):9899-904. Epub 2003 Dec 29.

6.

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

PLoS One. 2010 Jun 21;5(6):e11241. doi: 10.1371/journal.pone.0011241.

7.

Kinetic rationale for selectivity toward N- and C-terminal oxygen-dependent degradation domain substrates mediated by a loop region of hypoxia-inducible factor prolyl hydroxylases.

Flashman E, Bagg EA, Chowdhury R, Mecinović J, Loenarz C, McDonough MA, Hewitson KS, Schofield CJ.

J Biol Chem. 2008 Feb 15;283(7):3808-15. Epub 2007 Dec 5.

8.

Determination and comparison of specific activity of the HIF-prolyl hydroxylases.

Tuckerman JR, Zhao Y, Hewitson KS, Tian YM, Pugh CW, Ratcliffe PJ, Mole DR.

FEBS Lett. 2004 Oct 8;576(1-2):145-50.

9.

Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis.

Pappalardi MB, Martin JD, Jiang Y, Burns MC, Zhao H, Ho T, Sweitzer S, Lor L, Schwartz B, Duffy K, Gontarek R, Tummino PJ, Copeland RA, Luo L.

Biochemistry. 2008 Oct 28;47(43):11165-7. doi: 10.1021/bi801624f. Epub 2008 Oct 4.

PMID:
18834144
10.

Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases.

Bruegge K, Jelkmann W, Metzen E.

Curr Med Chem. 2007;14(17):1853-62. Review.

PMID:
17627521
12.

Inhibition of a prolyl hydroxylase domain (PHD) by substrate analog peptides.

Kwon HS, Choi YK, Kim JW, Park YK, Yang EG, Ahn DR.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4325-8. doi: 10.1016/j.bmcl.2011.05.050. Epub 2011 May 24.

PMID:
21665470
13.

Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors.

Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH, Acker T.

Cancer Res. 2010 Jan 1;70(1):357-66. doi: 10.1158/0008-5472.CAN-09-1876. Epub 2009 Dec 22.

14.

[Reciprocal regulation between hypoxia-inducible factor-1alpha and its prolyl hydroxylases in hypoxic pulmonary hypertension rats].

Chen YR, Dai AG, Hu RC.

Zhonghua Jie He He Hu Xi Za Zhi. 2006 Oct;29(10):668-73. Chinese.

PMID:
17129494
15.

Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor.

Linke S, Stojkoski C, Kewley RJ, Booker GW, Whitelaw ML, Peet DJ.

J Biol Chem. 2004 Apr 2;279(14):14391-7. Epub 2004 Jan 20.

16.

HIF hydroxylation and cellular oxygen sensing.

Metzen E, Ratcliffe PJ.

Biol Chem. 2004 Mar-Apr;385(3-4):223-30. Review.

PMID:
15134335
17.
18.

HIF-prolyl hydroxylases and cardiovascular diseases.

Sen Banerjee S, Thirunavukkarasu M, Tipu Rishi M, Sanchez JA, Maulik N, Maulik G.

Toxicol Mech Methods. 2012 Jun;22(5):347-58. doi: 10.3109/15376516.2012.673088. Review.

PMID:
22424133
19.

Regulation of HIF: asparaginyl hydroxylation.

Peet D, Linke S.

Novartis Found Symp. 2006;272:37-49; discussion 49-53, 131-40. Review.

PMID:
16686428

Supplemental Content

Support Center